How It Works
ProSomnus users report improved sleep without masks, hoses, or surgery, and its devices are compact and travel-friendly.
prosomnus.comCrawled Nov 18, 2026
ProSomnus users report improved sleep without masks, hoses, or surgery, and its devices are compact and travel-friendly.
ProSomnus provides free starter kits to help healthcare providers begin treating obstructive sleep apnea patients.
ProSomnus provides Instructions for Use (IFU) and user manuals for patients and healthcare professionals.
ProSomnus devices are preferred by patients, providers, and payers over CPAP and traditional oral appliances.
Dentist Jason Ehtessabian highlights the ease of delivery and patient comfort of ProSomnus EVO devices.
ProSomnus offers downloadable documents for its RPMO2 OSA device system, including user manuals and provider guides.
A ProSomnus survey with Prodege identifies obstacles to treating snoring and sleep issues.
Obstructive sleep apnea affects over 40 million adults in the U.S. and is linked to heart attacks, strokes, hypertension, diabetes, and heart failure.
ProSomnus HWO2 Quick Start Guide ProSomnus HWO2 Device User Manual ProSomnus Oxymetrx App User Manual ProSomnus HWO2 Consumer Brochure
ProSomnus Sleep Technologies announced a $168 million combination with Lakeshore Acquisition I Corp. in May, featuring a device for obstructive sleep apnea that avoids ventilator use.
Shareholders of Lakeshore Acquisition I Corp. approved the business combination with ProSomnus, with 92.4% voting in favor.
ProSomnus enrolled the first patient in its Severe Obstructive Sleep Apnea (SOS) study, evaluating the safety and efficacy of its device.
ProSomnus was named to Inc. Magazine’s Inc. 5000 list of America’s fastest-growing private companies for 2022, marking its fourth consecutive year on the list.
SAN FRANCISCO, March 17, 2022 (GLOBE NEWSWIRE) — ProSomnus Sleep Technologies, the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced a donation to the International Rescue Committee (IRC) to support families displaced from Ukraine. ProSomnus will donate a portion of the proceeds from every full-price ProSomnus EVOTM Sleep and ... Read more
Laing Rikkers, Executive Chairwoman of ProSomnus, participated in the Oppenheimer Private Company Showcase in October 2022.
ProSomnus and Lakeshore Acquisition I Corp. announced a definitive business combination agreement, with the combined company expected to operate as ProSomnus, Inc.
ProSomnus delivers precision non-CPAP oral appliance therapy for obstructive sleep apnea, with integrated multi-night physiologic monitoring via its RPMO2 platform.
ProSomnus holds patents for intraoral medical devices designed to treat obstructive sleep apnea, a condition tied to heart failure, stroke, hypertension, obesity, and diabetes.
ProSomnus pioneers non-CPAP oral appliance therapy for obstructive sleep apnea, integrating multi-night physiologic monitoring via its RPMO2 platform.
ProSomnus develops precision oral appliances for obstructive sleep apnea treatment, with a focus on market access, scientific studies, and public health.
ProSomnus Therapy offers a restful sleep solution without CPAP machines, masks, or hoses, used by thousands of patients.